AUM $7.5MER 0.47%NAV $37.34Holdings 68Inception Aug 2022
Price Chart
Key Statistics
Previous Close
$37.33Day Range
$37.45$37.50
52-Week Range
$25.42$40.67
Avg Volume
2.6KDividend Yield
1.00%Expense Ratio
0.47%AUM
$7.5MShares Outstanding
159.3KETF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 73.19% |
| Ireland | 4.55% |
| Netherlands | 4.43% |
| Canada | 4.37% |
| South Korea | 2.59% |
| Sweden | 2.34% |
| Denmark | 1.85% |
| Australia | 1.62% |
| Switzerland | 1.57% |
| China | 1.00% |
| Japan | 1.00% |
| France | 0.63% |
| Israel | 0.42% |
| Italy | 0.28% |
| Other | 0.16% |
Fund Information
- Issuer
- iShares
- Category
- Healthcare
- Types
- GrowthTechnology
- Inception Date
- Aug 24, 2022
- Exchange
- NYSE_ARCA
- Description
- The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
Similar ETFs
The iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund issued by iShares that launched on Aug 24, 2022. It currently manages $7.5M in assets under management. The fund charges an expense ratio of 0.47%. The fund holds 68 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 45.1% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | PRAX | PRAXIS PRECISION MEDICINES | 5.25% | 1,157 | $400K |
| 2 | DNTH | DIANTHUS THERAPEUTICS INC | 5.14% | 3,652 | $391K |
| 3 | ACAD | ACADIA PHARMACEUTICALS | 4.83% | 13,265 | $367K |
| 4 | SRRK | SCHOLAR ROCK HOLDING | 4.77% | 6,638 | $363K |
| 5 | XENE | XENON PHARMACEUTICALS | 4.41% | 5,685 | $335K |
| 6 | ARWR | ARROWHEAD PHARMACEUTICALS | 4.37% | 4,021 | $332K |
| 7 | ARGX | ARGENX SE ADR | 4.35% | 330 | $331K |
| 8 | BIIB | BIOGEN | 4.17% | 1,505 | $317K |
| 9 | ALKS | ALKERMES | 4.10% | 6,870 | $312K |
| 10 | PTCT | PTC THERAPEUTICS | 3.68% | 4,145 | $280K |
| 11 | NBIX | NEUROCRINE BIOSCIENCES | 3.66% | 1,793 | $278K |
| 12 | EWTX | EDGEWISE THERAPEUTICS | 3.51% | 6,153 | $267K |
| 13 | AXSM | AXSOME THERAPEUTICS | 3.50% | 1,265 | $266K |
| 14 | DNLI | DENALI THERAPEUTICS | 3.31% | 11,666 | $252K |
| 15 | DYN | DYNE THERAPEUTICS | 2.61% | 10,352 | $199K |
Page 1 of 2
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +0.44% | |
| 1W | -4.18% | |
| 1M | -4.28% | |
| 3M | +6.90% | |
| 6M | +19.11% | |
| YTD | +17.74% | |
| 1Y | +46.59% | |
| 3Y | +66.46% | |
| 5Y | +52.33% |
Moving Averages
20-Day MA
$39.24
Below 20-Day MA50-Day MA
$38.65
Below 50-Day MA200-Day MA
$34.59
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$40.67
Current Price
$37.49
52-Week Low
$25.42
$25.42$40.67
Current Yield
1.00%
Annual Dividend
$0.7471
Frequency
Annualx/year
Last Ex-Date
Dec 16, 2025
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $0.3198 | Dec 19, 2025 |
| Dec 16, 2025 | $0.3198 | Dec 19, 2025 |
| Dec 17, 2024 | $0.1011 | Dec 20, 2024 |
| Dec 20, 2023 | $0.0063 | Dec 27, 2023 |
| Jun 7, 2023 | $0.0082 | Jun 13, 2023 |
Dividend Payments Over Time
Category Comparison
| Metric | IBRN | Healthcare(254 ETFs) | Growth(409 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.47% | 0.62% | 0.66% |
| AUM | $7.5M | $1.73B | $3.10B |
| Dividend Yield | 1.00% | 3.97% | 5.84% |
| Avg Volume | 2.6K | 364.4K | 166.5K |
| Holdings | 68 | 160 | 80 |
| Performance | |||
| 1-Month Return | -4.37% | -2.86% | -2.46% |
| 6-Month Return | +8.06% | +7.23% | +4.66% |
| YTD Return | +15.80% | +10.59% | +9.34% |
| 1-Year Return | +17.03% | +8.50% | +8.84% |
Compare with Another ETF
Search for an ETF to compare with IBRN:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.